Hanall Biopharma Future Growth

Future criteria checks 4/6

Hanall Biopharma is forecast to grow earnings and revenue by 45.9% and 12.5% per annum respectively. EPS is expected to grow by 45.6% per annum. Return on equity is forecast to be 18% in 3 years.

Key information

45.9%

Earnings growth rate

45.6%

EPS growth rate

Pharmaceuticals earnings growth	33.8%
Revenue growth rate	12.5%
Future return on equity	18.0%
Analyst coverage	Good
Last updated	01 Apr 2024

Recent future growth updates

Recent updates

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Mar 13

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Feb 12

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Jan 25

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 04

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Dec 14

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Nov 21

Earnings and Revenue Growth Forecasts

KOSE:A009420 - Analysts future estimates and past financials data (KRW Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	231,000	44,000	41,600	44,600	1
12/31/2025	164,233	12,400	700	9,460	6
12/31/2024	143,633	7,383	-5,367	3,900	6
12/31/2023	134,910	3,509	20,445	29,643	N/A
9/30/2023	133,308	6,049	20,416	29,933	N/A
6/30/2023	129,981	6,464	2,674	10,464	N/A
3/31/2023	114,812	-919	10,070	18,024	N/A
12/31/2022	109,995	251	17,587	25,264	N/A
9/30/2022	104,764	-376	10,636	20,123	N/A
6/30/2022	100,596	949	10,515	20,067	N/A
3/31/2022	97,783	4,288	1,719	12,083	N/A
12/31/2021	101,594	8,896	-8,162	840	N/A
9/30/2021	98,500	16,123	72	6,659	N/A
6/30/2021	95,140	17,778	-4,183	1,719	N/A
3/31/2021	94,304	20,413	-5,913	1,778	N/A
12/31/2020	88,602	19,765	-6,460	929	N/A
9/30/2020	92,953	19,714	-20,156	-7,468	N/A
6/30/2020	98,834	21,457	1,452	14,085	N/A
3/31/2020	106,049	19,753	13,739	22,030	N/A
12/31/2019	108,452	19,174	12,215	20,491	N/A
9/30/2019	105,550	10,279	22,576	24,374	N/A
6/30/2019	101,531	7,373	10,174	11,694	N/A
3/31/2019	94,252	5,882	3,130	5,117	N/A
12/31/2018	91,839	3,300	-4,913	-2,994	N/A
9/30/2018	88,551	9,000	26,226	28,359	N/A
6/30/2018	89,131	9,149	26,945	28,894	N/A
3/31/2018	87,204	6,945	31,363	33,291	N/A
12/31/2017	84,231	5,813	39,931	42,139	N/A
9/30/2017	85,417	3,586	N/A	7,912	N/A
6/30/2017	81,809	562	N/A	-325	N/A
3/31/2017	81,807	1,355	N/A	2,825	N/A
12/31/2016	82,882	2,026	N/A	3,950	N/A
9/30/2016	82,223	-3,478	N/A	6,046	N/A
6/30/2016	79,584	-5,817	N/A	6,546	N/A
3/31/2016	79,447	-7,142	N/A	2,205	N/A
12/31/2015	80,023	-7,077	N/A	-454	N/A
9/30/2015	79,818	-16,050	N/A	1,128	N/A
6/30/2015	81,892	-13,143	N/A	280	N/A
3/31/2015	81,657	-12,865	N/A	-1,115	N/A
12/31/2014	80,880	-12,658	N/A	-3,518	N/A
9/30/2014	78,763	-11,694	N/A	-6,993	N/A
6/30/2014	77,511	-17,134	N/A	-5,677	N/A
3/31/2014	76,276	-18,966	N/A	-8,556	N/A
12/31/2013	74,228	-21,499	N/A	-7,780	N/A
9/30/2013	74,338	-9,978	N/A	-8,969	N/A
6/30/2013	76,161	-4,201	N/A	-2,822	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A009420's forecast earnings growth (45.9% per year) is above the savings rate (2.5%).

Earnings vs Market: A009420's earnings (45.9% per year) are forecast to grow faster than the KR market (28.4% per year).

High Growth Earnings: A009420's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: A009420's revenue (12.5% per year) is forecast to grow faster than the KR market (9.1% per year).

High Growth Revenue: A009420's revenue (12.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A009420's Return on Equity is forecast to be low in 3 years time (18%).

Hanall Biopharma Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

Price target increased by 14% to ₩35,800

Price target decreased to ₩29,000

Price target decreased to ₩45,500

Recent updates

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Hanall Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: ₩69.00 (vs ₩5.00 in FY 2022)

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

New major risk - Share price stability

Price target increased by 14% to ₩35,800

Now 20% undervalued

Full year 2022 earnings released: EPS: ₩5.00 (vs ₩174 in FY 2021)

Less than half of directors are independent

Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner

Price target decreased to ₩29,000

Less than half of directors are independent

Price target decreased to ₩45,500

First quarter 2021 earnings released: EPS ₩88.00 (vs ₩76.00 in 1Q 2020)

Hanall Biopharma Co.,Ltd, Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS ₩386 (vs ₩375 in FY 2019)

New 90-day low: ₩23,400

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Investor sentiment deteriorated over the past week

New 90-day low: ₩32,050

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: ₩39,000

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Market bids up stock over the past week

New 90-day low: ₩27,600

Price target raised to ₩41,500

New 90-day high - ₩34,600

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies